← Leaderboards
Cynthia A Moylan
Duke University
$5,972,949
Attributed
$16,353,394
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,353,394 · 6
VA$0 · 1
By mechanism
UH3$10,038,112 · 1
U01$2,522,568 · 2
UG3$2,219,249 · 1
R01$1,193,886 · 1
R21$379,579 · 1
I01$0 · 1
Top collaborators
- Cathrine Hoyo9 shared
- Joellen M. Schildkraut5 shared
- Anna Mae Elizabeth Diehl4 shared
- Susanna Naggie4 shared
- Raymond T Chung3 shared
- Yujin Hoshida3 shared
- Matthew R. Kappus1 shared
Most similar at Duke University
Same institution · by research overlap
- Huiman X Barnhart$28,912,069
- Stacy Michelle Horner$8,997,349
- Ravi R. Jhaveri$579,471
- Rae Jean Elizabeth Proeschold-Bell$1,745,597
- Shelton Stewart Bradrick$696,854
Others in their field
Other Emerging Leaders on “Liver”
- Amit Singal · Ut Southwestern Medical Center$14,118,934
- Barbara Halina Braffett · George Washington University$9,972,097
- Ionut Bebu · George Washington University$9,972,097
- Jennifer Cohen Price · University Of California, San Francisco$9,725,541
- William Raymond Lagor · Baylor College Of Medicine$8,988,713
- William H. Peranteau · Children'S Hosp Of Philadelphia$7,624,302
Research focus
LiverCirrhosisCessation Of LifeMortalityUnited StatesNon-Alcoholic Fatty Liver DiseaseObesityFibrosisCohortPrimary Carcinoma Of The Liver CellsAdultLiver DiseasesLiver FibrosisMediatingResponseCase ControlTissuesLiver CirrhosisLongitudinal Cohort StudyAlcohol ConsumptionNorth CarolinaFollow-UpMalignant NeoplasmsMetabolic
Grant awards (20)
Southern Liver Health Cohort$4,968,641
UH3 · FY2025 · CA
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis$628,059
U01 · FY2025 · CA
Genomic Imprinting in the Development of NAFLD$584,695
R01 · FY2025 · DK · contact PI
Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis$376,893
U01 · FY2025 · DK · contact PI
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy$0
I01 · FY2025 · VA
Southern Liver Health Cohort$2,579,511
UH3 · FY2024 · CA
Genomic Imprinting in the Development of NAFLD$609,191
R01 · FY2024 · DK · contact PI
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis$323,446
U01 · FY2024 · CA
Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis$72,480
U01 · FY2024 · DK · contact PI
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy$0
I01 · FY2024 · VA
Southern Liver Health Cohort$2,489,960
UH3 · FY2023 · CA
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis$366,710
U01 · FY2023 · CA
Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis$264,919
U01 · FY2023 · DK · contact PI
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy$0
I01 · FY2023 · VA
Southern Liver Health Cohort$1,080,860
UG3 · FY2022 · CA
Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis$490,061
U01 · FY2022 · DK
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy$0
I01 · FY2022 · VA
Southern Liver Health Cohort$1,138,389
UG3 · FY2021 · CA
Hepatocellular Carcinoma, Epigenetics and Cadmium Exposure$132,881
R21 · FY2020 · CA
Hepatocellular Carcinoma, Epigenetics and Cadmium Exposure$246,698
R21 · FY2019 · CA